A Pure Herbal Prophylactic Contraceptive for HIV Infection

A novel active principle of plant origin i.e. the compound Acaciaside-B obtained from the extract of the seeds of Acacia auriculiformis, and/or enriched fraction, its derivatives, analogues and pharmaceutically acceptable salts thereof and/or its mixture with other synthetic or natural substances are used as virucidal and spermicidal agents.
The compound is isolated from the plant Acacia auriculiformis. The infectivity of HIV and motility of spermatozoa are inhibited simultaneously by the said compound. Ac-B and/or enriched fraction is utilized for the preparation of prophylacticformulations useful against HFV and as spermicidal agent.
The invention also provides a method of topical application of Ac-B in any suitable formulation of any suitable form as protection against HIV-I infection in organs including mammalian rectum where prevention of HIV transmission is a primary objective.
Ac-B possesses anti-HIV property at a tolerably low concentration, is non-mutagenic and does not harm the niche of Lactobacilli. Thus Ac-B appears to be a superior ingredient for formulations of a chemical barrier against HIV-I infection wherein its spermicidal property is superfluous.
Thus the invention relates to a provide a pharmaceutical having virucidal property, which is capable of acting as a chemical barrier against HIV-I infection (AIDS) along with a superfluous spermicidal property, which can be deployed as a prophylactic formulation/contraceptive that would provide a convenient, readily available method of self protection against AIDS and/or unwanted pregnancy.

Anti-HIV formulation. An active principle for the preparation of OTC formulations, available as emergency protection against HIV-I infection during heterosexual invasive contact and/or vaginal contraceptive.
A method for simultaneous prevention of HIV infection and unwanted pregnancy in a subject, comprising administering a therapeutically effective amount of the compound Ac-B, derivatives, analogues and pharmaceutically acceptable salts

Ac-B has an anti-HIV property and capable to prevent HIV infection at a dose level of greater than or equal to 1.0 microgram per ml in vitro, which is perhaps well within tolerable limits ( Hemolytic index: 7 microgram per ml).
MEC of Ac-B is 125micro g/ml for spermicidal activity on human sperm which is significantly lower than that of closest prior arts (MEC for N-9:200-500 microgram/ml through vaginal route.
Significant spermicidal as well as virucidal activities with apparently no possible mutagenic effects and adverse effects on vaginal ecology. Ac-B is non-mutagenic as tested in Ames Test.
Ac-B does not interfere with the growth of Lactobacillus acidophilus in laboratory culture, at least up to a concentration of 500 mg/ml. Thus it application does not lead to an increased risk of opportunistic infections.
Its molecular size is about three fold higher than N-9, which makes it likely to be absorbed weekly through vaginal route.